MarketPeel
Insider Trading Intelligence
GF

Gregory R. Friberg

BMRN
EVP, CHIEF R&D OFFICER · BIOMARIN PHARMACEUTICAL INC · CIK 0002038768
FILING MIX · LIFETIME64%/36%
BUYS
7
SELLS
4
TOTAL VALUE
$828.9K
COMPANIES
1
ACTIVE SINCE
Sep 2024
HOLDINGS NOW
51,818
AVG SELL PX
$57.01
TRADE KIND
SHOWING 11 / 11
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 8 pending
Forward-return performance of every backtestable P/S trade by Gregory R. Friberg, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+100.00%-1.38%+0.15%-1.53%-1.53%
14d2+100.00%-5.78%-3.37%+0.03%+0.03%
30d2+50.00%-3.25%-3.60%+0.35%+0.35%
60d2(1 pending)+100.00%-11.95%+3.75%-15.70%-15.70%
90d2(1 pending)+100.00%-13.47%
180d2(2 pending)
1y2(2 pending)
2y2(2 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
BMRN · 51,818 shares · as of May 7, 2026
014,18228,36442,54656,72820252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 7 buys / 4 sellsCOVERAGE · 8 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
BMRN
BIOMARIN PHARMACEUTICAL INC
SALE
EVP, Chief R&D Officer
3,281$53.85$176.7K51,818May 7, 2026May 11, 2026View →
BMRN
BIOMARIN PHARMACEUTICAL INC
SALE
EVP, Chief R&D Officer
1,629$56.05$91.3K55,099Mar 17, 2026Mar 18, 2026View →
BMRN
BIOMARIN PHARMACEUTICAL INC
PURCHASEGRANT
Stock grant
19,15056,728Mar 16, 2026Mar 18, 2026View →
BMRN
BIOMARIN PHARMACEUTICAL INC
PURCHASEGRANT
Stock grant
45,60045,600Mar 16, 2026Mar 18, 2026View →
BMRN
BIOMARIN PHARMACEUTICAL INC
SALE
EVP, Chief R&D Officer
6,326$60.38$381.9K37,578Feb 26, 2026Feb 26, 2026View →
BMRN
BIOMARIN PHARMACEUTICAL INC
SALE
EVP, Chief R&D Officer
3,304$54.16$178.9K43,506Sep 30, 2025Oct 2, 2025View →
BMRN
BIOMARIN PHARMACEUTICAL INC
PURCHASEGRANT
Stock grant
41,17041,170Mar 17, 2025Mar 18, 2025View →
BMRN
BIOMARIN PHARMACEUTICAL INC
PURCHASEGRANT
Stock grant
17,75046,810Mar 17, 2025Mar 18, 2025View →
BMRN
BIOMARIN PHARMACEUTICAL INC
PURCHASEGRANT
Stock grant
49,85049,850Sep 30, 2024Oct 1, 2024View →
BMRN
BIOMARIN PHARMACEUTICAL INC
PURCHASEGRANT
Stock grant
21,19021,190Sep 30, 2024Oct 1, 2024View →
BMRN
BIOMARIN PHARMACEUTICAL INC
PURCHASEGRANT
Stock grant
7,87029,060Sep 30, 2024Oct 1, 2024View →
Other insiders · BMRN
Loading peer insiders…
About this filer
CIK 0002038768
ROLE
EVP, Chief R&D Officer
PRIMARY
BMRN
COMPANIES
1
ACTIVE SINCE
Sep 2024
MARKETPEEL · /INSIDER/0002038768DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback